Raffaele Califano, MD / Nicolas Girard, MD, PhD / Antonio Passaro, MD, PhD - Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

Please visit answersincme.com/860/98320325-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the evolving role of HER2-targeted antibody–drug conjugates (ADCs) and how to integrate them into clinical practice. Upon completion of this activity, participants should be better able to: Recognize the role of biomarker testing for the management of HER2-overexpressing NSCLC; Evaluate the clinical significance of new and emerging HER2-targeting ADCs for HER2-overexpressing NSCLC; and Apply strategies to optimize the use of HER2 targeting ADCs in patients with NSCLC.

There are no comments yet.

Please log in to write the first comment.